Related Experiment Videos
Interferon-induced vasospasm in chronic myeloid leukaemia
A Zeidman1, D Dicker, M Mittelman
1Department of Medicine B, Rabin Medical Center, Golda (Hasharon) Campus, Petah-Tikva, Israel.
Acta Haematologica
|October 30, 1998
Summary
Interferon (IFN) effectively treats chronic myeloid leukaemia (CML), but rare vasospasm complications can occur. Awareness and dose adjustment are key for managing these rare adverse effects in CML patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Interferon (IFN) is a standard treatment for chronic myeloid leukaemia (CML).
- While effective, IFN therapy can cause various adverse effects.
- Vasospastic complications are exceptionally rare in patients receiving IFN for CML.
Observation:
- Two CML patients developed rare vasospastic complications during IFN therapy.
- One patient experienced anginal syndrome and acute ischemia, while the other developed Raynaud's phenomenon.
- Both patients showed resolution of symptoms after IFN discontinuation or dose adjustment.
Findings:
- IFN treatment for CML can be associated with rare but serious vasospastic events, including cardiac ischemia and Raynaud's phenomenon.
- Discontinuation of IFN or administration of prostacyclin analogues like iloprost can resolve these vascular complications.
- The study highlights the need for vigilance regarding rare adverse effects of IFN in CML management.
Implications:
- Clinicians should be aware of the potential for rare vasospastic complications in CML patients treated with IFN.
- Lowering IFN dosage may be a viable strategy for patients achieving cytogenetic response, especially if vascular adverse events arise.
- Further research is needed to establish clear guidelines for managing IFN-induced vasospasm in CML.